Genenta Science S.p.A. (GNTA)

3.2830 -0.4170 (-11.27%) As of 02:30PM EDT. Market open.

Genenta Science S.p.A.

Via Olgettina No. 58
Milan, MI 20132
Italy

https://www.genenta.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 14

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pierluigi Paracchi	Vice Chairman of the Board, CEO & GM	N/A	N/A	1973
Dr. Luigi Naldini M.D., Ph.D.	Co-Founder & Chairman of the Executive Scientific Board	N/A	N/A	1959
Dr. Bernard Rudolph Gentner M.D., Ph.D.	Co-Founder & Member of the Executive Scientific Board	N/A	N/A	1975
Mr. Richard B. Slansky	Chief Financial Officer	N/A	N/A	1958
Dr. Carlo Russo M.D.	Chief Medical Officer & Head of Development	N/A	N/A	1953
Dr. Stefania Mazzoleni Ph.D.	Director of Program Development	N/A	N/A	1982
Ms. Barbara Regonini	Director of Finance	N/A	N/A	1973

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Corporate governance

Genenta Science S.p.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.